A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma

BACKGROUND: Uveal melanoma is a disease characterized by constitutive activation of the G alpha pathway and downstream signaling of protein kinase C (PKC) and the mitogen-activated protein kinase (MAPK) pathway. While limited clinical activity has been observed in patients with metastatic disease wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Sebastian, Larkin, James, Hodi, F. Stephen, Stephen, Frank, Kapiteijn, Ellen H. W., Schwartz, Gary K., Calvo, Emilano, Yerramilli-Rao, Padmaja, Piperno-Neumann, Sophie, Carvajal, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288853/
https://www.ncbi.nlm.nih.gov/pubmed/37359242
http://dx.doi.org/10.3389/fonc.2022.975642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288853/
https://www.ncbi.nlm.nih.gov/pubmed/37359242
http://dx.doi.org/10.3389/fonc.2022.975642

Ejemplares similares